WCE 2017: MR Targeted Prostate Biopsy Against Standard Ultrasound Guided Prostate Biopsy - A Single Center Experience: First Results

Vancouver, Canada (UroToday.com) Dr. Ömer Levent Huncay, urology professor at the Pamukkale Universtiy School of Medicine, Turkey, described his findings on his center’s experience on magnetic resonance imaging (MRI) for targeted prostate biopsy rather than transrectal ultrasound (TRUS), the current, internationally accepted procedure for detecting prostate cancer. Dr. Huncay explained to the audience how MRI guided biopsy (Bx) has been shown to reduce the detection of low-risk cancer and increase the detection of intermediate and high-risk cancer, while using fewer cores. 

The study consisted of a cohort of 38 men between August, 2016 to February, 2017 all from the Pamukkale Medical Center. 18 men were diagnosed with benign pathology. For the remaining 20 men, biopsies were taken using multi-parametric (mp) MRI for eight patients, TRUS for one patient, and both TRUS and mpMRI for 11 patients. 

mpMRI Bx was used for 117 cores from 42 lesions with a mean core of 2.7 per patient. Prostate cancer positive core number was 53. For TRUS Bx, 456 cores were taken from 38 lesions, with an mean of 12 cores per patient. Prostate cancer positive core number was 27. 

Dr. Huncay concluded his presentation by explaining his stance on prostate biopsy. His findings determined that mpMRI Bx is more efficient than standard biopsy by utilizing less cores and is more accurate at diagnosing cancer. 

Presented by: Ömer Levent Huncay, MD   

Authors: Erhan Firat, Yusuf Özlülerden, Ömer Levent Huncay, Ahmet Baki Yağci
Affiliation: Pamukkale Universtiy School of Medicine Department of Urology – Turkey  

Written by: Zachary Valley, Department of Urology, University of California-Irvine at the 35th World Congress of Endourology– September 12-16, 2017, Vancouver, Canada.